MoonLake Immunotherapeutics (MLTX) Earnings History
Net Loss6 years of earnings data (2020–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
MoonLake Immunotherapeutics (MLTX) Earnings Overview
As of June 29, 2026, MoonLake Immunotherapeutics (MLTX) reported trailing twelve-month net income of -$257M, reflecting -86.8% year-over-year growth. The company earned $-3.61 per diluted share over the past four quarters.
Looking at the long-term picture, MLTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$90,838 in fiscal 2020.
MoonLake Immunotherapeutics is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including UCB ($341M net income, 21.4% margin), NKTR (-$158M net income, -297.1% margin), ARQT (-$2M net income, -4.3% margin), MLTX has comparable earnings metrics. Compare MLTX vs UCB →
MLTX Earnings vs Peers
Earnings metrics vs comparable public companies
MLTX Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$227M | -91.1% | -$245M | $-3.53 | - | - |
| 2024 | -$119M | -230.3% | -$143M | $-1.89 | - | - |
| 2023 | -$36M | +27.9% | -$54M | $-0.73 | - | - |
| 2022 | -$50M | +6.8% | -$65M | $-2.20 | - | - |
| 2021 | -$54M | -58954.2% | -$54M | $-1.45 | - | - |
| 2020 | $-90,838 | - | $-105,755 | $-0.01 | - | - |
Download Data
Export MLTX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
MLTX — Frequently Asked Questions
Quick answers to the most common questions about buying MLTX stock.
What is MLTX earnings per share (EPS)?
MLTX trailing twelve-month (TTM) diluted EPS is $-3.61, reflecting -86.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2020 to 2025 is available in the table on this page.
What is MoonLake Immunotherapeutics's net income?
MoonLake Immunotherapeutics (MLTX) trailing twelve-month net income is $-257M as of 2025. Earnings declined -86.8% year-over-year.
Is MLTX profitable?
MLTX is not currently profitable on a TTM basis, reporting a net loss of $-257M. Net margin is N/A. Investors should monitor for a return to profitability.
What is MLTX's earnings growth rate?
MLTX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2020 to 2025.
What are MLTX's profit margins?
MoonLake Immunotherapeutics net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -60.0%.
Is MLTX growing earnings?
MLTX earnings are declining — EPS fell -86.8% year-over-year. TTM net income dropped to $-257M. This contrasts with the 5-year CAGR of N/A.
What was MLTX's best earnings year?
MoonLake Immunotherapeutics's highest annual net income on record is $-90838.00, achieved in fiscal year 2020. Earnings history on this page spans 2020 to 2025 and includes all annual and quarterly figures.
What were MLTX's earnings last quarter?
MLTX's most recent reported quarter was Q1 2026. Net income was $-70M with diluted EPS of $-0.98. For a full breakdown of all quarters, see the quarterly earnings table on this page.